scientific directory 2015 - 2019

Scientific
Directory
2015 - 2019

Scientific
Directory
2015 - 2019

Gustave Roussy was first created as
the “Institut du Cancer” by Pr. Gustave
Roussy in 1926 and gathers on its campus
around 3,000 professionals, including 239
MD, whose missions are to treat cancer
patients, to set up innovative therapies and
to develop and spread the knowledge within
medical and scientific communities.
The Institute is headed by Pr. Alexander
Eggermont and its specificity is based
on the integration between innovative
healthcare and a top level research through
a tight cooperation with the Université
Paris-Sud and its Faculty of Medicine.
In 2014, the Institute ensured 228,000
medical consultations and hosted 11,800
new patients, 26% of whom have benefited
from an innovative therapy through the
enrollment in one of the 369 ongoing clinical
studies.
Since January 1st 2015, the Chevilly-Larue
hospital (CHSP) has merged with Gustave
Roussy; which increased the total number
of hospital beds up to 435 and of outpatient
units up to 102.
The Gustave Roussy research landscape now
comprises 37 research teams (from basic
science to translational biological research,
from epidemiology and biostatistics to
psycho-oncology and health economy), 14
clinical research teams each focused on
one organ or pathology, a clinical research
division which manages all the aspects of the
clinical research (methodology, biostatistics,
regulatory affairs, operations and
pharmacovigilance), a hospital department
dedicated to therapeutic innovations and
early clinical trials as well as a 10 technology
core facilities brought together within one
administrative “Service Unit”. Research at
Gustave Roussy is coordinated by Pr. Eric
Solary.
In the last years, a global reflection has
been initiated about the evolution of the
technologies core facilities within Gustave
Roussy. As far as genomics is concerned,
Gustave Roussy has externalised the high-
throughput sequencing for the molecular
medicine program (through a partnership
with a biotech company, INTEGRAGEN,
which installed and operates a “clinical
sequencing unit” within the Institute), and
proposes to merge its 2 genomics facilities
(for clinical and basic research) within a
unique facility that can share expertise,
personnel and technology.
The robotised fluorescence videomicroscopic
facility for high-throughput screening
is now available and the creation of a
“pharmacology Platform” for clinical and
basic research is envisioned. Moreover, the
management of the Tumour Bank (~150,000
tumor samples) is being profoundly
modified to give a better access to tumour
samples and to store biological samples
upon prospective research programs.
The Molecular Medicine Program has been
refined by new trial designs with the aim
to answer the question of resistance to
targeted therapies (i.e. MATCH-R) including
sequential biopsies and xenografts.
The Gustave Roussy Immunotherapy
Program (GRIP) has been initiated following
the recruitment of clinical immunologist
who is setting up immunotherapy clinical
trials associated with translational
research.
The onco-haematology program will be
reinforced by the creation of the hospital
haematology department which will give
visibility and coherence to the haematology
clinical activities and foster collaboration
with Gustave Roussy research teams.
According to the SAB 2013 recommendations,
several cross-program research projects
are being developed (e.g linking immunology
and DNA repair).
The development of the clinical research
has been mainly focused on early phase
clinical trials through the creation of
the Drug Development department
dedicated to therapeutic innovations and
Alexander Eggermont
Director General Eric Solary Director of Gustave Roussy Research
early clinical trials, the recruitment of a
senior methodologist specialised in early
phase trial and adaptive designs, and the
coordination of the Institute’s industrial
partnerships.
The present book introduces research groups
and clinical committees currently operating
in Gustave Roussy and the platforms they
use. DNA repair, tumour immunology and
molecular medicine are the three main axes of
basis and translational research, with clinical
research introducing new drugs and testing
biomarkers.
Strengthening international partnerships
Internationally, Gustave Roussy is developing a
program to promote its model of care, to train
foreign professionals, and to improve access
to cancer care for all patients through hospital
projects abroad, which may be one-off or occur
several times a year.
These have taken place in partner countries
such as Kazakhstan, Kuwait and the United
Arab Emirates.
On the research side, the Institute played a key
role in the founding, in July 2014, of “Cancer Core
Europe”, a European comprehensive cancer
center consortium that involves 5 other Cancer
Centres (DKFZ / NCT, VHIO, NKI, Cambridge
Cancer Center, Karolinska Institute). Cancer
Core Europe will make the bridge «bench-to-
bedside and bedside-to-bench» and conduct
next-generation clinical trials focused on
proof-of-concept, companion, predictive and
resistance monitoring, biomarkers.
Several working groups have been set up,
among which the “IT/ Data Sharing working
group” will develop a common software
platform to integrate all patient data that
federates the databases from each of the
centres. In less than a year, the consortium has
already been successful in two European calls:
TRANSCAN and EIT Health.
Gustave Roussy has drawn its future roadmap
through its Development Program 2015-2020.
Resulting from several months of work by all
the professionals at the Institute, it provides a
framework, based on existing foundations, for
an innovative Comprehensive Cancer Centre.
Within this program, the three main actions
for research are: (i) the creation of clinician-
researchers positions (MD/PhD or PharmaD/
PhD) whose workload will be mainly focused
on ambitious exploratory and/or translational
research projects; (ii) the construction of a
preclinical cancer research facility (PRECAN);
(iii) the creation in 2020 of a renewed Research
Centre endorsed by the National Institutions
(including basic, translational and clinical
research).
This last objective is highly strategic. The
Institute aims at building on an integrated,
first-class, innovative research based on
highly-talented scientists, clinicians and staff
members. After evaluating the potential of
candidate research team leaders, a proposal
for a future research strategy and organisation
of the Research Centre will be discussed, in a
very open system of exchange.

76
RESEARCH KEY NUMBERS FROM 20122014
A growing part of IF>20
within the total number
of publications
Number of PublicatioNs iN Peer review jourNal
Number of PatieNts iNcluded iN cliNical studies by sPoNsor
research workforce (full time equivaleNt - fte) 113 Phd studeNts iNcludiNg 41% of NoN-freNch Phd studeNts
coNsolidated budget (m€)
research workforce
key Numbers 2014
124 142
2013 20142012
0
400
800
1200
200
600
1000
1400
180
Academic (except GR)
Industrials
Gustave Roussy
Total
France
Europe
Russia
Asia
India
Latin America
North Africa
Middle East
Research Teams and
technologicals facilities (Others)
Clinical Research (GR)
Research Teams and
Technological facilities (GR)
Total Research Manpower
2 813
3 690
3 308
2013 20142012
0
1 000
1 500
2 000
3 000
3 500
4 000
500
2 500
2013 20142012
0
40
60
80
20
100
2013 20142012
879,5 972,4
822,85
0
400
600
800
200
1 000
The consolidated budget corresponds to ALL research
expenses for any research activity on Gustave Roussy
Campus, given that these expenses can be incurred
by Gustave Roussy or not (i.e. salaries of the academic
positions, grants that are managed in other institutions, etc.)
70,1
90,1 85,5
972 Full Time Equivalent (FTE) assigned to the Research Division, including
• 656 FTE employed by Gustave Roussy in the Technological facilities, Clinical Research and Research Teams,
• 316 FTE not employed by Gustave Roussy (Inserm, CNRS, Paris-Saclay University, others) in the Research
Teams and Technological Facilities
67
4
6
4
1
11
1
19
PatieNts iNcluded iN cliNical studies
• 3 308 patients included in clinical studies including 434 patients in early phase clinical trials
• 331 ongoing clinical trial including 86 early phase clinical trials
• 30 % of Gustave Roussy’s new patients included in a clinical study
PublicatioNs iN Peer review jourNal
• 1150 publications in peer review journals
including 180 in journals whose IF>10
Pub IF <10
Pub IF>10

UMR 981 INSERM: PREDICTIVE BIOMARKERS AND NEW MOLECULAR
STRATEGIES FOR CANCER THERAPY
Fabrice André P. 17
UMR 1170 INSERM: NORMAL AND MALIGNANT HAEMATOPOIESIS
Olivier Bernard P. 19
Genetic and Epigenetic control of normal and malignant haematopoiesis
(ATIP-AVENIR)
Camille Lobry P. 20
Genetic and modelling of paediatric leukaemia
Thomas Mercher P. 21
Endocytosis, cytoskeleton and cell migration (ATIP-AVENIR)
Guillaume Montagnac P. 22
Early steps of haematopoietic transformation
Virginie Penard Lacronique, Olivier Bernard P. 23
haematopoietic stem cells to the differentiation of megakaryocytes
Hana Raslova P. 24
From haematopoietic stem cell to myelomonocytic differentiation
Eric Solary, Françoise Porteu P. 25
UMR 8081 CNRS: MAGNETIC RESONANCE IMAGING AND MULTIMEDICAL TERMS IR4M
Luc Darrasse
Multimodal imaging in oncology
Nathalie Lassau P. 27
UMR 1030 INSERM: MOLECULAR RADIOTHERAPY
Eric Deutsch P. 29
Tumour Response to Radiation Therapy
Eric Deutsch, Nazanine Modjtahedi P. 30
Cell death and Aging team
Jean-Luc Perfettini P. 31
UMR 1018 INSERM  CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION
HEALTH CESP
Bruno Falissard P. 32
Scientific Directory 2015 - 2019
1. RESEARCH TEAMS Lifestyle, genes and health: integrative trans-generational epidemiology
Marie-Christine Boutron-Ruault P. 33
Methodology and Clinical Epidemiology in Molecular Oncology
Stefan Michiels P. 34
Radiation Epidemiology, Clinical Epidemiology of cancer and survival
Florent de Vathaire P. 35
UMR 9196 CNRS: MOLECULAR PHYSIOLOGY AND PATHOLOGY OF
INFECTIOUS AND ENDOGENOUS RETROVIRUSES
Thierry Heidmann P. 37
UMR 8200 CNRS: GENETIC STABILITY AND ONCOGENESIS
Patricia Kannouche P. 38
Cell division and genomic stability
Olivier Gavet P. 39
TLS Polymerases and Genome Plasticity
Patricia Kannouche, Said Aoufouchi P. 40
Recombination, Repair, ROS and Cancer
Bernard Lopez, Corinne Dupuy P. 41
Repair of double strand breaks and genome integrity (ATIP-AVENIR)
Gerard Mazon P. 42
Replication stress, genomic instability and mitosis (ERC Starting Grant)
Valeria Naim P. 43
DNA repair Syndromes
Filippo Rosselli P. 44
DNA repair
Murat Saparbaev P. 45
UMR 1138 INSERM: APOPTOSIS, CANCER & IMMUNITY
Guido Kroemer P. 47
UMR 1186 INSERM: INTEGRATIVE TUMOUR IMMUNOLOGY
AND GENETIC ONCOLOGY
Fathia Mami-Chouaib P. 49
Oncogenesis and tumour progression in melanoma (ATIP-AVENIR)
Mehdi Khaled
P. 50
Integrative Tumour Immunology and Genetic Oncology
Fathia Mami-Chouaib P. 51